INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 431m ago
HOUSE PTR30m ago
SEC 13F30m ago
ROBINHOOD CHAIN30m ago
SEC FORM 4/Grant or awardVerified data

Townsend Richard Nolan reported LXEO

Director, Chief Executive Officer · Lexeo Therapeutics, Inc. · Common Stock

Side
A
Value
—
Shares
161.7K
Price
—
Executed
Feb 4, 2026
Disclosed
Feb 6, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 4 executedFeb 6, 2026 disclosed

LXEO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 67.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LXEO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    12
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A$6,097
    2,306 sh
    		Sep 14, 2026Sep 28, 2026
    traded Sep 14, 2026
    		+14dSEC FORM 4

    Evidence

    2
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    145.5K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    15
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A$5,579
    2,110 sh
    		Sep 14, 2026Sep 28, 2026
    traded Sep 14, 2026
    		+14dSEC FORM 4

    Evidence

    5
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    54.8K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    15
    BP
    Bhalla Narinder PalChief Medical Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A$9,713
    2,714 sh
    		Sep 14, 2026Sep 28, 2026
    traded Sep 14, 2026
    		+14dSEC FORM 4

    Evidence

    5
    BP
    Bhalla Narinder PalChief Medical Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    54.8K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    5
    TE
    Tamayo Louis EdwardChief Financial Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    54.8K sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    27
    TE
    Tamayo Louis EdwardChief Financial Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$20K
    4,117 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    27
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$17K
    3,345 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    27
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$6,464
    1,304 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    39
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$116K
    25.9K sh
    		Jul 1, 2026Jul 1, 2026
    traded Jul 1, 2026
    		+0dSEC FORM 4

    Evidence

    32
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$21K
    4,666 sh
    		Jul 1, 2026Jul 1, 2026
    traded Jul 1, 2026
    		+0dSEC FORM 4

    Evidence

    9
    OM
    Otero Jose ManuelChief Operating Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    12.1K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    36
    TE
    Tamayo Louis EdwardChief Financial Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$21K
    4,641 sh
    		Jul 1, 2026Jul 1, 2026
    traded Jul 1, 2026
    		+0dSEC FORM 4

    Evidence

    13
    TE
    Tamayo Louis EdwardChief Financial Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    12.0K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    47
    BP
    Bhalla Narinder PalChief Medical Officer
    LXEOLexeo Therapeutics, Inc.
    Open-market sale
    		SELL$99K
    22.3K sh
    		Jul 1, 2026Jul 1, 2026
    traded Jul 1, 2026
    		+0dSEC FORM 4

    Evidence

    21
    BP
    Bhalla Narinder PalChief Medical Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    55.0K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TN
    Townsend Richard NolanDirector, Chief Executive Officer
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    67.0K sh
    		Jun 29, 2026Jul 1, 2026
    traded Jun 29, 2026
    		+2dSEC FORM 4

    Evidence

    9
    VT
    Van Hauwermeiren TimothyDirector
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    35.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AK
    Agger Mette KirstineDirector
    LXEOLexeo Therapeutics, Inc.
    Grant or award
    		A—
    35.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001995218-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 4, 2026
    Published
    Feb 6, 2026
    Ingested by INSIDER
    Nov 5, 04:18 UTC
    Last re-read
    Nov 5, 04:18 UTC

    Extracted facts

    Filer
    Townsend Richard Nolan
    Role
    Director, Chief Executive Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Lexeo Therapeutics, Inc.
    Ticker
    LXEO
    Shares
    161.7K
    Price per share
    $0
    Execution date (reported)
    Feb 4, 2026
    Owned after transaction
    402.7K shares
    Days from execution to publication
    2

    What this establishes

    Townsend Richard Nolan filed this Form 4 reporting a grant or award of LXEO on Feb 4, 2026. It became public on Feb 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Townsend Richard Nolancik:0001995218
    Issuer
    Lexeo Therapeutics, Inc.cik:0001907108

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.